RO 7795081
Alternative Names: CT-996; RG-6652; RO-7795081Latest Information Update: 01 Dec 2025
At a glance
- Originator Carmot Therapeutics
- Developer Carmot Therapeutics; Roche
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
- Phase I Unspecified
Most Recent Events
- 01 Dec 2025 Roche plans to file a regulatory application of RO 7795081 in Obesity and Type 2 diabetes mellitus in 2028 or beyond (Roche pipeline, December 2025)
- 10 Nov 2025 Phase-I clinical trials in Obesity (In volunteers) in Netherlands (PO) (CTIS2025-522766-78-00; EudraCT-2025-522766-78-00)
- 10 Nov 2025 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Netherlands (PO) (CTIS2025-522766-78-00; EudraCT-2025-522766-78-00)